CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-05 | Warmuth Markus President & CEO | Sale | −10,135 | $15.17 | $154K | 624,403 |
| 2026-01-05 | Janku Filip Chief Medical Officer | Sale | −3,155 | $15.17 | $48K | 75,026 |
| 2026-01-05 | Townson Sharon Chief Scientific Officer | Sale | −3,155 | $15.17 | $48K | 67,845 |
| 2026-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award | +28,000 | 64,000 | ||
| 2026-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +126,000 | 126,000 | ||
| 2026-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award | +35,000 | 65,000 | ||
| 2026-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +158,000 | 158,000 | ||
| 2026-01-02 | Warmuth Markus President & CEO | Grant or award | +90,000 | 634,538 | ||
| 2026-01-02 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +406,000 | 406,000 | ||
| 2026-01-02 | Janku Filip Chief Medical Officer | Grant or award | +31,000 | 78,181 | ||
| 2026-01-02 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +139,000 | 139,000 | ||
| 2026-01-02 | Townson Sharon Chief Scientific Officer | Grant or award | +35,000 | 71,000 | ||
| 2026-01-02 | Townson Sharon Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +158,000 | 158,000 | ||
| 2025-06-13 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2025-06-13 | Hughes Eric A Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2025-06-13 | Manning Anthony M. Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2025-06-13 | Blackwell Kimberly Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2025-06-13 | Siu Christine Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2025-06-13 | Skvarka Jan Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2025-06-13 | SCHIFF ANDREW N Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 |
Page 5 of 9 · 174 trades